Health Care

African-American men with prostate cancer show stronger response to hormone therapy

African-American men with prostate cancer show stronger response to hormone therapy

Such patients had experienced "an unbelievable response", he said. "If we can prove that in the planned new trial, it should be possible to provide some men with advanced prostate cancer with an exciting new treatment option".

World-leading prostate cancer expert Professor Johann de Bono, of the Institute for Cancer Research, said: 'We hope for a cure but we can't call it that yet.

With regard to patients' definitive prostate cancer treatment, 186 (94%) patients had undergone radical prostatectomy (RP) and the remaining 11 (6%) received external beam radiation therapy (EBRT).

Two years ago, he was given the immunotherapy drug pembrolizumab.

It is the first time immunotherapy has been shown to benefit some men with prostate cancer, the researchers said.

Yes! Now the prostate cancer patients with hardly weeks or months to live will be able to survive longer if they are subjected to proper immunotherapy treatment.

Researchers from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust in London gave 258 men with the otherwise untreatable cancer the immunotherapy agent Keytruda (pembrolizumab). The drugs alter the body's immune system that focuses directly on tackling cancer. While just 5 percent men who were a part of the trail actually saw their cancer to shrink or disappear after receiving the treatment, many of those had heavily mutated cancers.

Sky Sports' PGA Tour future in jeopardy
Three years ago, the Silver Spring, Md. -based programmer acquired the pan-European media rights to the Olympics . Discovery will distribute tour events on its regular TV channels and a new streaming service.

However, the therapy will not work for most patients.

Prof de Bono said the drug was "well tolerated" by patients "with relatively few severe side effects". These are medications which boost the immune system, and here trials have shown combination treatments to have have saved the lives of some men who were diagnosed with terminal prostate cancer.

Only around 20% of cancer patients respond to immunotherapy and researchers do not fully understand why.

"One of the major challenges with immunotherapy is that we don't have many reliable tests to pick out who will benefit".

The researchers also said that some of the patients who had substantial responses to the treatment have tumors that may have mutations in the genes that control DNA fix, an important cellular process that maintains the genome.

Eight months of treatment with abiraterone (AA) plus leuprolide for biochemically recurrent non-metastatic hormone-naive prostate cancer (M0HNPC) improves PSA-free survival compared with the use of leuprolide alone, with no delay in testosterone recovery or significant safety concerns, according to data presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, on Monday, June 4.